- Home
- ENTA vs SGHT Comparison
ENTA vs SGHT Comparison
Compare ENTA & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- SGHT
- Stock Information
- Founded
- ENTA 1995
- SGHT 2011
- Country
- ENTA United States
- SGHT United States
- Employees
- ENTA N/A
- SGHT N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- SGHT Medical Specialities
- Sector
- ENTA Health Care
- SGHT Health Care
- Exchange
- ENTA Nasdaq
- SGHT Nasdaq
- Market Cap
- ENTA 154.0M
- SGHT 140.1M
- IPO Year
- ENTA 2013
- SGHT 2021
- Fundamental
- Price
- ENTA $5.59
- SGHT $2.44
- Analyst Decision
- ENTA Buy
- SGHT Buy
- Analyst Count
- ENTA 4
- SGHT 7
- Target Price
- ENTA $17.25
- SGHT $3.83
- AVG Volume (30 Days)
- ENTA 228.9K
- SGHT 285.1K
- Earning Date
- ENTA 05-05-2025
- SGHT 03-05-2025
- Dividend Yield
- ENTA N/A
- SGHT N/A
- EPS Growth
- ENTA N/A
- SGHT N/A
- EPS
- ENTA N/A
- SGHT N/A
- Revenue
- ENTA $66,590,999.00
- SGHT $79,866,000.00
- Revenue This Year
- ENTA N/A
- SGHT $3.09
- Revenue Next Year
- ENTA N/A
- SGHT $13.61
- P/E Ratio
- ENTA N/A
- SGHT N/A
- Revenue Growth
- ENTA N/A
- SGHT N/A
- 52 Week Low
- ENTA $4.71
- SGHT $2.17
- 52 Week High
- ENTA $17.80
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- ENTA 31.66
- SGHT 42.43
- Support Level
- ENTA $5.65
- SGHT $2.64
- Resistance Level
- ENTA $5.96
- SGHT $3.13
- Average True Range (ATR)
- ENTA 0.36
- SGHT 0.23
- MACD
- ENTA -0.15
- SGHT -0.02
- Stochastic Oscillator
- ENTA 4.77
- SGHT 8.90
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.